186 related articles for article (PubMed ID: 19296223)
1. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs.
Friedmann PD; Jiang L; Alexander JA
J Behav Health Serv Res; 2010 Jul; 37(3):322-37. PubMed ID: 19296223
[TBL] [Abstract][Full Text] [Related]
2. Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.
Savage SA; Abraham AJ; Knudsen HK; Rothrauff TC; Roman PM
J Subst Abuse Treat; 2012 Jan; 42(1):16-24. PubMed ID: 21831565
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
Koch AL; Arfken CL; Schuster CR
Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
[TBL] [Abstract][Full Text] [Related]
4. Community treatment programs take up buprenorphine.
Casadonte PP; Kolodner GF; Horton T; McMurphy SM
Sci Pract Perspect; 2004 Aug; 2(2):24-9. PubMed ID: 18552729
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.
Knudsen HK; Abraham AJ; Johnson JA; Roman PM
J Subst Abuse Treat; 2009 Oct; 37(3):307-12. PubMed ID: 19577406
[TBL] [Abstract][Full Text] [Related]
6. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.
Andrews CM; D'Aunno TA; Pollack HA; Friedmann PD
Med Care Res Rev; 2014 Feb; 71(1):43-60. PubMed ID: 24051897
[TBL] [Abstract][Full Text] [Related]
7. Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.
Wallack SS; Thomas CP; Martin TC; Chilingerian J; Reif S
J Behav Health Serv Res; 2010 Jan; 37(1):64-78. PubMed ID: 18668369
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
Knudsen HK; Ducharme LJ; Roman PM; Link T
J Subst Abuse Treat; 2005 Sep; 29(2):95-106. PubMed ID: 16135338
[TBL] [Abstract][Full Text] [Related]
9. State policy influence on the early diffusion of buprenorphine in community treatment programs.
Ducharme LJ; Abraham AJ
Subst Abuse Treat Prev Policy; 2008 Jun; 3():17. PubMed ID: 18570665
[TBL] [Abstract][Full Text] [Related]
10. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors.
Knudsen HK; Ducharme LJ; Roman PM
J Subst Abuse Treat; 2006 Jun; 30(4):363-73. PubMed ID: 16716852
[TBL] [Abstract][Full Text] [Related]
11. Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.
Heinrich CJ; Cummings GR
Health Serv Res; 2014 Feb; 49(1):127-52. PubMed ID: 23855719
[TBL] [Abstract][Full Text] [Related]
12. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
[TBL] [Abstract][Full Text] [Related]
13. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
[TBL] [Abstract][Full Text] [Related]
14. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption.
Ducharme LJ; Roman PM
J Subst Abuse Treat; 2009 Jul; 37(1):90-4. PubMed ID: 19004597
[TBL] [Abstract][Full Text] [Related]
15. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program.
Levy S; Vaughan BL; Angulo M; Knight JR
J Adolesc Health; 2007 May; 40(5):477-82. PubMed ID: 17448411
[TBL] [Abstract][Full Text] [Related]
17. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
18. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
Health Aff (Millwood); 2019 Jan; 38(1):14-23. PubMed ID: 30615514
[TBL] [Abstract][Full Text] [Related]
19. Proliferation of Cash-Only Buprenorphine Treatment Clinics: A Threat to the Nation's Response to the Opioid Crisis.
Van Zee A; Fiellin DA
Am J Public Health; 2019 Mar; 109(3):393-394. PubMed ID: 30726142
[No Abstract] [Full Text] [Related]
20. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
